Updates in the Management of Triple Negative BC: Review article | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 34, Volume 92, Issue 1, July 2023, Page 5687-5691 PDF (528.8 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.307718 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Eman Ibrahim Abdelshakour  ; Emad Eldin Nabil Hassan; Elsayed Mostafa Ali
| ||||
| Abstract | ||||
| Breast cancer (BC), which is predicted to impact 1.67 million individuals a year, is the disease with the second highest mortality rate worldwide, the most common cancer in women, and ranks fifth among causes of cancer-related death. BC is the most prevalent form of cancer among Egyptian women. Objective: This review article aimed to investigate for the updates in the management of triple negative BC (TNBC). Methods: We searched PubMed, Google Scholar, and Science Direct for relevant articles on: Trible negative breast cancer, updates and management. Only the most recent or thorough studies were taken into account between 2005 and January 2023. The authors also evaluated the value of resources culled from other works in the same genre. Documents written in languages other than English have been ignored due to a lack of translation funds. Unpublished works, oral presentations, conference abstracts, and dissertations were generally agreed upon not to be qualified as scientific research. Conclusion: Egypt National Cancer Institute (NCI) reported that at the end of 2001, among 10, 556 patients BC represented 18.9% of all cancer cases (35.1% in females and 2.2% in men). Approximately 60%–70% of BC patients are hormone-receptor positive and 20%–25% have amplified HER2. Clinically, ER, PR, and HER2 expression in primary BC tissue is utilised to identify biological subtypes, forecast outcomes, and to determine the optimal course of treatment, particularly for endocrine and HER2-targeted regimens. Targeted treatments targeting one of the aforementioned targets (ER, PR, or HER2) are available for the majority of patients, when patients are identified with tumours that lack ER, PR, or HER2, these therapy options are not available. These BCs are known as triple negative breast cancers. TNBC is a subtype of BC that makes up 15% of all cases. It can be recognised by the loss of ER and PR expression, as well as the absence of HER2/neu oncogene amplification or overexpression. | ||||
| Keywords | ||||
| BC; Triple negative; Chemotherapy; Targeted therapy | ||||
|
Statistics Article View: 141 PDF Download: 306 |
||||
